Our Scientific Publications
Our list of scientific publications is still being updated. You can find Prof. Dr. Mutlu Demiray's publications on his Google Scholar profile. View Google Scholar profile
13 publications
May 19, 2026A First in Thoracic SMARCA4-Deficient Undifferentiated Tumor: Dual Immunotherapy Plus CDK4/6 InhibitionIn our patient with a chemorefractory, PD-L1-negative but high tumor mutational burden thoracic SMARCA4-deficient undifferentiated tumor, dual immunotherapy (pembrolizumab plus ipilimumab) was combined with the CDK4/6 inhibitor palbociclib for the first time, producing a partial metabolic response within 1.5 months.July 1, 2025Elacestrant in the Post-CDK4/6 Inhibitor Setting: A Precision Oncology View of HR+/HER2- Breast CancerOur editorial on how to choose treatment once resistance to CDK4/6 inhibitors has developed examines the place of elacestrant in the light of the EMERALD subgroup analyses, and argues that the decision should be personalized according to mutations such as ESR1 and PIK3CA.May 12, 2025Exceptional Improvement in Advanced Kidney Cancer with Genomic Profiling and a Smart Drug Combination (Immunotherapy + Temsirolimus + Bevacizumab)In a patient with advanced kidney cancer, an exceptional response was achieved through a precision-guided smart-drug treatment based on the patient's personal genetic map (a combination of Immunotherapy, Temsirolimus and Bevacizumab).February 6, 2025Treatment Adaptation in IDH2-Mutant Biliary Tract Cancer: A Durable Response with Venetoclax and DecitabineIn metastatic biliary tract cancer progressing despite standard treatments, the venetoclax and decitabine regimen used in blood cancers was adapted on the basis of an IDH2 mutation found in the tumor. The tumors shrank markedly and the response lasted for 15 months.January 21, 2025Overcoming Smart Drug Resistance: Near-Complete Response with a Neratinib-Based Combination After T-DXdIn an HR+/HER2+ metastatic breast cancer patient who developed resistance to T-DXd, the tumor's genetic map was redrawn. After the HER2 pathway was shown to remain active at the RNA level, a combination of neratinib, fulvestrant and paclitaxel produced a near-complete response in the liver metastases.November 12, 2024A First in Co-Mutated ESR1 and PIK3CA Disease: The Elacestrant and Alpelisib CombinationIn a metastatic breast cancer patient carrying both ESR1 and PIK3CA mutations who had already received many lines of treatment, the elacestrant and alpelisib combination was used for the first time in the literature. Made tolerable through dose adjustment and ketogenic diet support, the treatment produced a marked regression in the liver and bone metastases.October 8, 2024Pan-Cancer Analysis of Rare BRAF Mutations: Potential Sensitivity to EGFR-Targeted TreatmentsThe genomic data of 376,302 cancer patients were examined to map the pan-cancer landscape of class III BRAF mutations. Alterations conferring resistance to EGFR-targeted drugs proved to be less frequent in these tumors, and two patients achieved long-lasting responses with EGFR-targeted treatment.September 29, 2024A Complete Response with Personalized Immunotherapy in "Cold Tumor" Adenoid Cystic CarcinomaAlthough the conventional immunotherapy biomarkers were negative, dual immunotherapy chosen on the basis of the frameshift and splice site mutations found in the tumor's genomic profile produced a complete radiologic response in our patient with radiotherapy- and chemotherapy-refractory metastatic adenoid cystic carcinoma.July 1, 2024FLT3 and MRD: Molecular Clues That Changed the Direction of Treatment in Metastatic Colon CancerIn a patient with colon cancer with liver metastasis who had received intensive chemotherapy and radiotherapy and had undergone surgery, MRD monitoring revealed early on that the response to treatment was insufficient. An FLT3 copy number gain, rarely encountered in colon cancer, was identified as a resistance factor and targeted, and the patient's tumor disappeared completely.May 22, 2024A Durable "Complete Response" with Immunotherapy in an HIV-Positive Patient with UV-Driven Head and Neck CancerA striking case report published in the medical literature reveals how a patient living with HIV, who developed lower-lip cancer due to sun-related (UV) damage, completely and durably beat the cancer with immunotherapy (nivolumab).